Approval · Notice of Compliance 15312 · 2014
NU-DIVALPROEX: Notice of Compliance 15312
Issued February 24, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15312
- Date
- February 24, 2014
- Company
- Nu-Pharm IncVaughan, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Addition of an alternate drug substance manufacturer
- Therapeutic class
- Antiepileptic
- Canadian reference product
- EPIVAL (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NU-DIVALPROEX | Not yet assigned | — |
Medicinal ingredients
- DIVALPROEX SODIUM 125 MG per TAB
- DIVALPROEX SODIUM 250 MG per TAB
- DIVALPROEX SODIUM 500 MG per TAB